PNU-159682-loaded EGFR-targeting Nanocells E-EDV-D682

**Semantic type:** Pharmacologic Substance

**Definition:** A nanocell formulation composed of bacterially derived nanospheres targeting the tumor-associated antigen (TAA) epidermal growth factor receptor (EGFR) using bispecific antibodies (bsAb) and packaged with the antineoplastic anthracycline PNU-159682, with potential antineoplastic and immunomodulating activities. Upon administration of PNU-159682-loaded EGFR-targeting nanocells E-EDV-D682, the nanocells are stable in the bloodstream and the anti-EGFR bsAb moiety targets and binds to EGFR-expressing tumor cells. Upon binding, the nanocell allows for specific delivery of PNU-159682 to tumor cells. Upon endocytosis by the tumor cells, the nanocell is broken down and releases PNU-159682, which intercalates into DNA and interferes with topoisomerase II activity, thereby inhibiting DNA replication and RNA synthesis, and inducing apoptosis. The nanocell fragments further activate the immune response and induce a cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response, thereby further killing tumor cells. Targeted delivery by the nanocells improves efficacy while lowering the toxicity profile. EGFR, a tyrosine kinase receptor, is overexpressed in many cancer cell types. The nanocell itself has no virulence.

**Synonyms:** - E-EDV-D 682 - E-EDV-D-682 - E-EDV-D682 - EGFR-targeted EDV Nanocells Carrying PNU-159682 E-EDV-D682 - EGFR-targeted EnGeneIC Dream Vectors Containing PNU-159682 E-EDV-D682 - EGFR-targeting PNU-159682-loaded EnGeneIC Delivery Vehicles E-EDV-D682 - PNU-159682-loaded EGFR-targeting EDVs E-EDV-D682